[go: up one dir, main page]

CA3109981A1 - Composes polycycliques et methodes pour la degradation ciblee de polypeptides du fibrosarcome rapidement accelere - Google Patents

Composes polycycliques et methodes pour la degradation ciblee de polypeptides du fibrosarcome rapidement accelere Download PDF

Info

Publication number
CA3109981A1
CA3109981A1 CA3109981A CA3109981A CA3109981A1 CA 3109981 A1 CA3109981 A1 CA 3109981A1 CA 3109981 A CA3109981 A CA 3109981A CA 3109981 A CA3109981 A CA 3109981A CA 3109981 A1 CA3109981 A1 CA 3109981A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
group
ulm
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3109981A
Other languages
English (en)
Inventor
Andrew P. Crew
Keith R. Hornberger
Jing Wang
Craig M. Crews
Saul Jaime-Figueroa
Hanqing Dong
Yimin Qian
Kurt Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Arvinas Operations Inc
Original Assignee
Yale University
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Arvinas Operations Inc filed Critical Yale University
Publication of CA3109981A1 publication Critical patent/CA3109981A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés bifonctionnels, ULM LPTM, qui s'avèrent utiles en tant que modulateurs du fibrosarcome rapidement accéléré (RAF, tel que c-RAF, A-RAF et/ou B-RAF ; la protéine cible). En particulier, la présente invention concerne des composés bifonctionnels, qui contiennent, au niveau d'une extrémité, un ligand de Von Hippel-Lindau, de céréblon, d'inhibiteurs de protéines d'apoptose ou d'homologue 2 double-minute de souris, qui se lie à l'ubiquitine ligase E3 respective, et, au niveau de l'autre extrémité, une fraction qui se lie à la protéine RAF cible, de sorte que la protéine cible se trouve à proximité de l'ubiquitine ligase pour effectuer la dégradation (et l'inhibition) de la protéine cible. La présente invention présente une large plage d'activités pharmacologiques associées à la dégradation/inhibition de la protéine cible. Les composés et les compositions selon la présente invention permettent de traiter ou de prévenir des maladies ou des troubles qui résultent de l'agrégation ou de l'accumulation de la protéine cible, ou de l'activation constitutive de la protéine cible.
CA3109981A 2018-09-07 2019-09-07 Composes polycycliques et methodes pour la degradation ciblee de polypeptides du fibrosarcome rapidement accelere Pending CA3109981A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728581P 2018-09-07 2018-09-07
US62/728,581 2018-09-07
PCT/US2019/050114 WO2020051564A1 (fr) 2018-09-07 2019-09-07 Composés polycycliques et méthodes pour la dégradation ciblée de polypeptides du fibrosarcome rapidement accéléré

Publications (1)

Publication Number Publication Date
CA3109981A1 true CA3109981A1 (fr) 2020-03-12

Family

ID=68051923

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109981A Pending CA3109981A1 (fr) 2018-09-07 2019-09-07 Composes polycycliques et methodes pour la degradation ciblee de polypeptides du fibrosarcome rapidement accelere

Country Status (9)

Country Link
EP (1) EP3846907A1 (fr)
JP (2) JP2022500368A (fr)
KR (2) KR20240028539A (fr)
CN (4) CN113164775B (fr)
AU (3) AU2019335516B2 (fr)
CA (1) CA3109981A1 (fr)
IL (2) IL319737A (fr)
MX (3) MX2021002559A (fr)
WO (1) WO2020051564A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
WO2019204354A1 (fr) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Composés spirocycliques
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
US20230099031A1 (en) * 2019-12-17 2023-03-30 Orionis Biosciences, Inc. Bifunctional agents for protein recruitment and/or degradation
CN115298173A (zh) * 2020-03-31 2022-11-04 田边三菱制药株式会社 羟基吡咯烷衍生物及其医药用途
WO2021255213A1 (fr) * 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Composés hétérobifonctionnels en tant qu'agents de dégradation de braf
WO2021255212A1 (fr) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Agents de dégradation de braf
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
EP4204418A1 (fr) * 2020-08-28 2023-07-05 Arvinas Operations, Inc. Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation
CN117062814A (zh) * 2020-08-28 2023-11-14 阿维纳斯运营公司 快速加速纤维肉瘤蛋白降解的化合物和相关使用方法
WO2022068849A1 (fr) * 2020-09-30 2022-04-07 Beigene, Ltd. Composés bifonctionnels pour la dégradation de l'egfr et procédés d'utilisation associés
WO2022152821A1 (fr) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Composés d'isoindolinone
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
WO2022266206A1 (fr) * 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras
WO2022270994A1 (fr) 2021-06-25 2022-12-29 한국화학연구원 Nouveau composé hétérocyclique bifonctionnel ayant une fonction de dégradation de btk par l'intermédiaire d'une voie de protéasome d'ubiquitine, et son utilisation
WO2023023941A1 (fr) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Agents de dégradation d'hpk1, compositions comprenant ces agents de dégradation d'hpk1 et leurs procédés d'utilisation
EP4421071A1 (fr) * 2021-10-22 2024-08-28 Gluetacs Therapeutics (Shanghai) Co., Ltd. Composé ligand de ligase e3 crbn, agent de dégradation de protéine développé sur la base d'un composé de ligand, et leurs utilisations
CN115894450B (zh) * 2021-11-30 2023-09-12 山东如至生物医药科技有限公司 一种新型多环类化合物及其组合物和用途
CN118488958A (zh) * 2021-11-30 2024-08-13 百济神州有限公司 用于降解egfr激酶的化合物
IL316803A (en) 2022-06-06 2025-01-01 C4 Therapeutics Inc Bicyclic glutarimide-modified cervalon-binding agents
TW202432544A (zh) 2022-09-07 2024-08-16 美商亞文納營運公司 快速加速纖維肉瘤降解化合物及相關使用方法
KR20250097910A (ko) * 2022-10-28 2025-06-30 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름) 포스파티딜이노시톨 3-키나제의 신규 억제제
CN115806503B (zh) * 2022-12-02 2025-03-07 中国海洋大学 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
WO2024245430A1 (fr) * 2023-05-31 2024-12-05 Beigene, Ltd. Composés pour la dégradation de la kinase egfr
WO2025094065A1 (fr) 2023-11-01 2025-05-08 Aurigene Oncology Limited Composés de pyridazine à substitution amino utilisés en tant qu'agents de dégradation de smarca2 et/ou de smarca4

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718300A4 (fr) 2004-01-16 2008-05-14 Univ Michigan Mimetiques de smac contraints de maniere conformationnelle et utilisations associees
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
WO2005097791A1 (fr) 2004-04-07 2005-10-20 Novartis Ag Inhibiteurs d'iap
WO2006014361A1 (fr) 2004-07-02 2006-02-09 Genentech, Inc. Inhibiteurs de pai
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
WO2007101347A1 (fr) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Composés de liaison au domaine bir
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
BRPI0810522B8 (pt) 2007-04-13 2021-05-25 Univ Michigan Regents compostos miméticos diazo bicíclicos de smac, composição farmacêutica e kit compreendendo ditos compostos e uso dos mesmos para o tratamento de câncer
EP2649099A4 (fr) 2010-12-07 2016-10-19 Univ Yale Marquage hydrophobe de petites molécules de protéines de fusion et dégradation induite de celles-ci
WO2013071039A1 (fr) 2011-11-09 2013-05-16 Ensemble Therapeutics Composés macrocycliques pour l'inhibition d'inhibiteurs de l'apoptose
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP2903998B1 (fr) 2012-10-02 2017-03-15 Bristol-Myers Squibb Company Antagonistes d'iap
EP3019517A1 (fr) 2013-07-12 2016-05-18 Bristol-Myers Squibb Company Antagonistes d'iap
KR20250127179A (ko) 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
HK1249058A1 (zh) * 2015-03-18 2018-10-26 Arvinas, Inc. 用於增强靶向蛋白质降解的化合物和方法
RU2018105094A (ru) * 2015-07-13 2019-08-14 Арвинас, Инк. Модуляторы протеолиза на основе аланина и связанные с ними способы применения
WO2017020010A1 (fr) * 2015-07-29 2017-02-02 Neuropore Therapies, Inc. Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
EP3544957B1 (fr) * 2016-11-22 2024-05-29 Dana-Farber Cancer Institute, Inc. Dégradation de protéines kinases par conjugaison d'inhibiteurs de protéine kinase avec un ligand de la ligase e3 et procédés d'utilisation
MX2019007649A (es) * 2016-12-23 2019-09-10 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.

Also Published As

Publication number Publication date
IL281188A (en) 2021-04-29
AU2022228150A1 (en) 2022-09-29
MX2024015414A (es) 2025-02-10
KR20240028539A (ko) 2024-03-05
MX2021002559A (es) 2021-07-21
EP3846907A1 (fr) 2021-07-14
IL319737A (en) 2025-05-01
AU2022228150B2 (en) 2024-06-20
CN119192142A (zh) 2024-12-27
AU2024219653A1 (en) 2024-10-03
AU2019335516A1 (en) 2021-03-11
IL281188B1 (en) 2025-04-01
KR102642203B1 (ko) 2024-03-04
CN113164775B (zh) 2025-03-18
JP2022500368A (ja) 2022-01-04
JP2023159166A (ja) 2023-10-31
AU2019335516B2 (en) 2022-06-16
IL281188B2 (en) 2025-08-01
WO2020051564A1 (fr) 2020-03-12
CN119101049A (zh) 2024-12-10
CN119219628A (zh) 2024-12-31
MX2024015415A (es) 2025-02-10
CN113164775A (zh) 2021-07-23
KR20210073519A (ko) 2021-06-18

Similar Documents

Publication Publication Date Title
AU2021200099B2 (en) Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CA3109981A1 (fr) Composes polycycliques et methodes pour la degradation ciblee de polypeptides du fibrosarcome rapidement accelere
AU2022221407B2 (en) Modulators of estrogen receptor proteolysis and associated methods of use
CA3042968C (fr) Derives de tetrahydronaphtalene et de tetrahydroisoquinoleine en tant qu'agents de degradation des recepteurs des oestrogenes
US11986531B2 (en) Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
AU2023248067A1 (en) Cereblon ligands and bifunctional compounds comprising the same
CA3095494A1 (fr) Modulateurs de proteolyse et procedes d'utilisation associes
CA3214806A1 (fr) Modulateurs de proteolyse bcl6 et procedes d'utilisation associes
RS66841B1 (sr) Jedinjenja za ciljanje brm i povezane metode upotrebe
CA3047586A1 (fr) Molecules chimeriques ciblant la proteolyse de l'egfr et procedes d'utilisation associes
CA2988430A1 (fr) Modulateurs de proteolyse a base de mdm2 et methodes d'utilisation associees
WO2017011590A1 (fr) Modulateurs de protéolyse à base d'alanine et procédés d'utilisation associés
RU2830173C2 (ru) Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы
RU2782458C2 (ru) Соединения и способы нацеленного расщепления полипептидов быстропрогрессирующей фибросаркомы

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217

EEER Examination request

Effective date: 20210217